טוען...
The Tuberculosis Drug Discovery and Development Pipeline and Emerging Drug Targets
The recent accelerated approval for use in extensively drug-resistant and multidrug-resistant-tuberculosis (MDR-TB) of two first-in-class TB drugs, bedaquiline and delamanid, has reinvigorated the TB drug discovery and development field. However, although several promising clinical development progr...
שמור ב:
| הוצא לאור ב: | Cold Spring Harb Perspect Med |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Cold Spring Harbor Laboratory Press
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4448709/ https://ncbi.nlm.nih.gov/pubmed/25635061 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/cshperspect.a021154 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|